产前伐昔洛韦治疗先天性巨细胞病毒感染的有效性与安全性:系统综述与Meta分析
该系统综述与Meta分析纳入8项研究共620名孕妇,评估产前伐昔洛韦治疗母体巨细胞病毒感染的有效性与安全性。结果显示,治疗组先天性巨细胞病毒感染风险显著低于未治疗组(合并OR 0.37,95%CI 0.21-0.64),但无症状感染风险升高(合并OR 2.98,95%CI 1.18-7.55),且证据质量极低。
要点
- 产前伐昔洛韦治疗与先天性巨细胞病毒感染风险降低相关(合并OR 0.37,95%CI 0.21-0.64)。
- 治疗组无症状先天性巨细胞病毒感染风险升高(合并OR 2.98,95%CI 1.18-7.55)。
- 所有不良事件发生率为3.17%(95%CI 1.24-5.93%),急性肾衰竭发生率为1.71%(95%CI 0.41-3.39%)。
核心结论
- 产前给予伐昔洛韦可降低母体巨细胞病毒感染孕妇的先天性巨细胞病毒感染风险,但需进一步证据阐明其能否影响胎儿感染病程及症状性胎儿或新生儿感染风险。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE、Cochrane数据库及ClinicalTrials.gov,纳入8项研究共620名孕妇。
- 纳入标准为确诊母体巨细胞病毒感染的妊娠,接受或未接受伐昔洛韦治疗。
- 采用Cochrane偏倚风险工具(RoB 2或ROBINS-I)评估偏倚风险,并进行头对头Meta分析。
主要发现
- 接受伐昔洛韦治疗的妊娠与未接受治疗者相比,先天性巨细胞病毒感染风险显著降低(3项研究,325例胎儿;合并OR 0.37,95%CI 0.21-0.64;I²=0%;P<0.001)。
- 按母体感染孕周分层,孕早期感染后接受伐昔洛韦者垂直传播风险显著降低(3项研究,184例胎儿;合并OR 0.34,95%CI 0.15-0.74;I²=20.9%;P=0.001),围受孕期或孕晚期感染两组无显著差异。
- 仅1项研究报告孕中期感染者的垂直传播风险,显示接受伐昔洛韦者先天性感染风险较低,但基于少数病例。
- 接受伐昔洛韦治疗的妊娠无症状先天性巨细胞病毒感染可能性高于未治疗者(2项研究,132例胎儿;合并OR 2.98,95%CI 1.18-7.55;I²=0%;P=0.021)。
- 两组围产期死亡(P=0.923)、终止妊娠(P=0.089)、孕期随访影像或出生时发现的异常(P=0.934)及新生儿巨细胞病毒感染症状(P=0.092)风险无显著差异。
局限性
- GRADE评估显示,伐昔洛韦降低先天性巨细胞病毒感染风险及不良围产结局的证据质量极低。
- 需进一步证据阐明伐昔洛韦能否影响胎儿感染病程及症状性胎儿或新生儿感染风险。
- 孕中期感染者的垂直传播风险分析仅基于1项研究且病例数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Universal screening for cytomegalovirus (CMV) infection in pregnancy is not recommended in most countries. One of the major deterrents is the lack of effective prenatal therapy. The role of valacyclovir therapy in reducing the risk of vertical transmission, symptomatic congenital CMV infection and adverse outcome is controversial. The main aim of this systematic review and meta-analysis was to investigate the safety and effectiveness of prenatal valacyclovir therapy in pregnancies with maternal CMV infection. METHODS: MEDLINE, EMBASE and Cochrane databases and ClinicalTrials.gov were searched. The inclusion criteria were pregnancy with confirmed maternal CMV infection, treated or untreated with valacyclovir. The primary outcome was the incidence of congenital CMV infection confirmed by a positive CMV polymerase chain reaction result of the amniotic fluid. The secondary outcomes were symptomatic and asymptomatic infection, perinatal death, termination of pregnancy, anomalies detected on follow-up ultrasound, on fetal magnetic resonance imaging or at birth, severe and mild-to-moderate symptoms due to congenital CMV infection, neurological, visual and hearing symptoms, and adverse events related to valacyclovir. Risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) or Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool, as appropriate. Head-to-head meta-analyses were used to compare the risk of each of the explored outcomes according to whether pregnancies with maternal CMV infection were treated with prenatal valacyclovir therapy. RESULTS: Eight studies (620 women) were included. Pregnancies treated with valacyclovir had a significantly lower risk of congenital CMV infection compared with those not receiving valacyclovir (three studies; 325 fetuses; pooled odds ratio (OR), 0.37 (95% CI, 0.21-0.64); I2 = 0%; P < 0.001). When stratifying the analysis according to gestational age at maternal infection, the risk of vertical transmission was significantly lower in pregnancies receiving valacyclovir following first-trimester maternal infection (three studies; 184 fetuses; pooled OR, 0.34 (95% CI, 0.15-0.74); I2 = 20.9%; P = 0.001), while there was no significant difference between the two groups in those acquiring CMV infection in the periconceptional period or in the third trimester of pregnancy. Only one study reported on the risk of vertical transmission in women infected in the second trimester, demonstrating a lower risk of congenital infection in women taking valacyclovir, although this was based on a small number of cases. Pregnancies treated with valacyclovir therapy had an increased likelihood of asymptomatic congenital CMV infection compared with those not receiving valacyclovir (two studies; 132 fetuses; pooled OR, 2.98 (95% CI, 1.18-7.55); I2 = 0%; P = 0.021), while there was no significant difference between the two groups in the risk of perinatal death (P = 0.923), termination of pregnancy (P = 0.089), anomalies detected at follow-up imaging assessment during pregnancy or at birth (P = 0.934) and symptoms due to CMV infection in the newborn (P = 0.092). The occurrence of all adverse events in pregnant individuals taking valacyclovir was 3.17% (95% CI, 1.24-5.93%) (six studies; 210 women), with 1.71% (95% CI, 0.41-3.39%) experiencing acute renal failure, which resolved after discontinuation of the drug. On GRADE assessment, the quality of evidence showing that valacyclovir reduced the risk of congenital CMV infection and adverse perinatal outcome was very low. CONCLUSIONS: Prenatal valacyclovir administration in pregnancies with maternal CMV infection reduces the risk of congenital CMV infection. Further evidence is needed to elucidate whether valacyclovir can affect the course of infection in the fetus and the risk of symptomatic fetal or neonatal infection. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- D'Antonio F, Marinceu D, Prasad S, et al. Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2023. PMID: 36484439. doi:10.1002/uog.26136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。